\u8bfa\u534e\u53ef\u5584\u633a\uff08\u53f8\u5e93\u5947\u5c24\u5355\u6297\uff09\u5f3a\u76f4\u6027\u810a\u67f1\u708e\u9002\u5e94\u75c7\u83b7\u6279
\u65f6\u95f4\uff1a2020-04-30 10:00:59 \u6765\u6e90\uff1a\u5317\u56fd\u7f51 \u4f5c\u8005\uff1a
(2020\u5e744\u670828\u65e5,\u4e2d\u56fd\u4e0a\u6d77)\u2014\u2014\u4eca\u5929,\u8bfa\u534e\u5236\u836f(\u4e2d\u56fd)\u5ba3\u5e03,\u53ef\u5584\u633a\u00ae (\u53f8\u5e93\u5947\u5c24\u5355\u6297)\u83b7\u5f97\u56fd\u5bb6\u836f\u54c1\u76d1\u7763\u7ba1\u7406\u5c40\u6279\u51c6,\u7528\u4e8e\u5e38\u89c4\u6cbb\u7597\u7597\u6548\u6b20\u4f73\u7684\u5f3a\u76f4\u6027\u810a\u67f1\u708e\u7684\u6210\u5e74\u60a3\u8005\u3002\u8fd9\u662f\u53ef\u5584\u633a\u00ae\u7ee72019\u5e743\u6708\u6279\u51c6\u7528\u4e8e\u6cbb\u7597\u4e2d\u91cd\u5ea6\u6591\u5757\u72b6\u94f6\u5c51\u75c5\u4e4b\u540e\u5728\u4e2d\u56fd\u83b7\u6279\u7684\u7b2c\u4e8c\u4e2a\u9002\u5e94\u75c7,\u4e5f\u662f\u76ee\u524d\u56fd\u5185\u9996\u4e2a\u4e14\u552f\u4e00\u88ab\u6279\u51c6\u7528\u4e8e\u6cbb\u7597\u5f3a\u76f4\u6027\u810a\u67f1\u708e\u7684\u767d\u4ecb\u7d20\u7c7b\u6291\u5236\u5242\u3002<\/p>\n\n\n\n
\u7814\u7a76\u53d1\u73b0,\u767d\u4ecb\u7d20-17A(IL-17A)\u662f\u4fc3\u8fdb\u708e\u75c7\u7ea7\u8054\u53cd\u5e94\u3001\u65b0\u9aa8\u751f\u6210\u3001\u6700\u7ec8\u5bfc\u81f4\u9aa8\u878d\u5408\u548c\u5b8c\u5168\u5f3a\u76f4\u7684\u91cd\u8981\u4ecb\u8d28\u3002\u4f5c\u4e3a\u76ee\u524d\u5168\u7403\u9996\u4e2a\u4e14\u552f\u4e00\u5168\u4eba\u6e90IL-17A\u6291\u5236\u5242,\u53ef\u5584\u633a\u00ae\u53ef\u7279\u5f02\u6027\u963b\u65ad\u4efb\u4f55\u6765\u6e90\u7684IL-17A,\u6709\u6548\u63a7\u5236\u708e\u75c7\u5e76\u6291\u5236\u65b0\u9aa8\u5f62\u6210,\u591a\u5c42\u8c03\u63a7\u75c5\u7406\u8fdb\u5c55\u3002<\/p>\n\n\n\n
\u8bfa\u534e\u5236\u836f(\u4e2d\u56fd)\u603b\u88c1\u5f20\u9896\u5973\u58eb\u8868\u793a:\u201c\u6211\u975e\u5e38\u9ad8\u5174\u53ef\u5584\u633a\u00ae\u80fd\u83b7\u6279\u7528\u4e8e\u4e2d\u56fd\u5f3a\u76f4\u6027\u810a\u67f1\u708e\u60a3\u8005\u7684\u6cbb\u7597,\u8fd9\u4e5f\u6807\u5fd7\u7740\u8bfa\u534e\u5728\u4e2d\u56fd\u8fdb\u5165\u98ce\u6e7f\u75be\u75c5\u9886\u57df\u3002\u5f3a\u76f4\u6027\u810a\u67f1\u708e\u591a\u8d77\u75c5\u4e8e\u4e2d\u9752\u5e74,\u75be\u75c5\u4e25\u91cd\u5f71\u54cd\u4e86\u60a3\u8005\u7684\u884c\u52a8\u80fd\u529b\u548c\u751f\u6d3b\u8d28\u91cf\u3002\u53ef\u5584\u633a\u00ae\u5f3a\u76f4\u9002\u5e94\u75c7\u7684\u83b7\u6279\u6709\u671b\u4e3a\u6570\u767e\u4e07\u4e2d\u56fd\u5f3a\u76f4\u60a3\u8005\u5e26\u6765\u5168\u65b0\u7684\u6cbb\u7597\u65b9\u6848\u548c\u5065\u5eb7\u5e0c\u671b,\u4f7f\u8bfa\u534e\u521b\u65b0\u836f\u7269\u60e0\u53ca\u66f4\u5e7f\u6cdb\u7684\u4e2d\u56fd\u60a3\u8005\u3002\u201d<\/p>\n\n\n\n
\u5f3a\u76f4\u6027\u810a\u67f1\u708e\u75be\u75c5\u8d1f\u62c5\u6c89\u91cd,\u201c\u6291\u5236\u9aa8\u7ed3\u6784\u8fdb\u5c55\u201d\u6cbb\u7597\u9700\u6c42\u4e9f\u5f85\u6ee1\u8db3<\/p>\n\n\n\n
\u5f3a\u76f4\u6027\u810a\u67f1\u708e\u662f\u4e00\u79cd\u6162\u6027\u708e\u75c7\u6027\u75be\u75c5,\u5c5e\u4e8e\u98ce\u6e7f\u514d\u75ab\u75c5\u3002\u5728\u6211\u56fd,\u5f3a\u76f4\u6027\u810a\u67f1\u708e\u60a3\u75c5\u7387\u7ea6\u4e3a0.3%,\u60a3\u75c5\u4eba\u6570\u7ea6\u5728300\u4e07\u5de6\u53f3<\/p>\n\n\n\n
\u3002\u53d1\u75c5\u5e74\u9f84\u901a\u5e38\u572813-31\u5c81,\u4e14\u591a\u89c1\u4e8e\u7537\u6027\u3002\u6570\u636e\u663e\u793a,\u7ea680%\u7684\u5f3a\u76f4\u6027\u810a\u67f1\u708e\u60a3\u8005\u5b58\u5728\u810a\u67f1\u75bc\u75db\u548c\u75b2\u52b3\u75c7\u72b6,\u6668\u50f5\u6bd4\u4f8b\u66f4\u662f\u9ad8\u8fbe90%\u3002\u4f46\u771f\u6b63\u53ef\u6015\u7684\u8fd8\u662f\u5b83\u53ef\u80fd\u5e26\u6765\u7684\u9aa8\u7ed3\u6784\u635f\u4f24\u3002<\/p>\n\n\n\n
\u6b63\u5e38\u60c5\u51b5\u4e0b,\u4eba\u4f53\u810a\u67f1\u690e\u4f53\u7531\u67d4\u97e7\u7684\u97e7\u5e26\u8fde\u63a5,\u56e0\u6b64\u8170\u80cc\u90e8\u53ef\u4ee5\u7075\u6d3b\u8fd0\u52a8\u3002\u97e7\u5e26\u4e0e\u4e0a\u4e0b\u690e\u4f53\u9aa8\u7684\u8fde\u63a5\u70b9\u88ab\u79f0\u4e3a\u9644\u7740\u70b9,\u800c\u5f3a\u76f4\u6027\u810a\u67f1\u708e\u60a3\u8005\u7684\u9644\u7740\u70b9\u5904\u4f1a\u53cd\u590d\u53d1\u751f\u708e\u75c7,\u751f\u51fa\u75c5\u7406\u6027\u65b0\u9aa8\u3002\u5065\u5eb7\u7684\u97e7\u5e26\u9010\u6e10\u5f00\u59cb\u9aa8\u5316,\u4ea7\u751f\u9aa8\u8d58\u3001\u8fde\u6210\u9aa8\u6865,\u6700\u7ec8\u5bfc\u81f4\u810a\u67f1\u878d\u5408\u5f3a\u76f4\u548c\u4e0d\u540c\u7a0b\u5ea6\u7684\u6b8b\u75be\u3002\u4e00\u9879\u4e2d\u56fd\u7814\u7a76\u663e\u793a,\u8d85\u8fc765%\u7684\u60a3\u8005\u4f34\u6709\u81f3\u5c11\u4e00\u4e2a\u97e7\u5e26\u9aa8\u8d58,\u8bf4\u660e\u76f8\u5f53\u6bd4\u4f8b\u7684\u60a3\u8005\u90fd\u5b58\u5728\u9aa8\u7ed3\u6784\u635f\u4f24\u4ee5\u53ca\u8fdb\u4e00\u6b65\u52a0\u91cd\u7684\u98ce\u9669\u3002<\/p>\n\n\n\n
301\u533b\u9662\u98ce\u6e7f\u79d1\u4e3b\u4efb\u533b\u5e08\u9ec4\u70fd\u6559\u6388\u4ecb\u7ecd:\u201c\u5f3a\u76f4\u6027\u810a\u67f1\u708e\u4f5c\u4e3a\u4e00\u79cd\u708e\u75c7\u6027\u75be\u75c5,\u6291\u5236\u708e\u75c7\u6c34\u5e73\u5f88\u91cd\u8981,\u4e5f\u662f\u76ee\u524d\u4e34\u5e8a\u836f\u7269\u6cbb\u7597\u7684\u91cd\u70b9\u3002\u4f46\u8fd1\u4e9b\u5e74\u6709\u7814\u7a76\u53d1\u73b0,\u5373\u4f7f\u708e\u75c7\u6c34\u5e73\u5f97\u5230\u63a7\u5236,\u4f9d\u7136\u4f1a\u5b58\u5728\u9aa8\u7ed3\u6784\u635f\u4f24\u8fdb\u4e00\u6b65\u6076\u5316\u7684\u60c5\u51b5\u3002\u5982\u4f55\u53cc\u7ba1\u9f50\u4e0b,\u7279\u522b\u662f\u2018\u6291\u5236\u9aa8\u7ed3\u6784\u8fdb\u5c55\u2019\u6210\u4e3a\u4e86\u4e9f\u5f85\u6ee1\u8db3\u7684\u6cbb\u7597\u9700\u6c42\u3002\u201d<\/p>\n\n\n\n
\u5168\u65b0\u9776\u70b9IL-17A\u201c\u7784\u51c6\u201d\u9aa8\u7ed3\u6784\u8fdb\u5c55,\u63a8\u52a8\u4e2d\u56fd\u5f3a\u76f4\u6027\u810a\u67f1\u708e\u751f\u7269\u5236\u5242\u6cbb\u7597\u633a\u8fdb\u5168\u65b0\u65f6\u4ee3<\/p>\n\n\n\n
\u5f3a\u76f4\u6027\u810a\u67f1\u708e\u4ece\u53d1\u75c5\u5230\u6700\u7ec8\u9aa8\u878d\u5408,\u4f1a\u7ecf\u5386\u51e0\u5927\u9636\u6bb5:\u9aa8\u708e-\u8102\u80aa\u6c89\u79ef-\u9aa8\u8d58-\u9aa8\u6865-\u9aa8\u878d\u5408\u3002\u201c\u65b0\u9aa8\u5f62\u6210\u201d\u662f\u6574\u4e2a\u75c5\u7a0b\u8fdb\u5c55\u7684\u75c5\u7406\u57fa\u7840,\u800cIL-17A\u662f\u4e2a\u91cd\u8981\u7684\u201c\u52a9\u63a8\u5668\u201d\u3002\u4e00\u65b9\u9762,\u5b83\u662f\u9644\u7740\u70b9\u708e\u53d1\u75c5\u8fc7\u7a0b\u4e2d\u7684\u5173\u952e\u7ec6\u80de\u56e0\u5b50\u548c\u708e\u75c7\u4ecb\u8d28,\u53ef\u8fdb\u4e00\u6b65\u4fc3\u8fdb\u708e\u75c7\u7ea7\u8054\u53cd\u5e94;\u53e6\u4e00\u65b9\u9762,\u5b83\u662f\u9aa8\u91cd\u5851\u7684\u5173\u952e\u4ecb\u8d28,\u53c2\u4e0e\u65b0\u9aa8\u5f62\u6210\u3002\u56e0\u6b64,\u6291\u5236IL-17A\u53ef\u963b\u65ad\u708e\u75c7\u901a\u8def\u3001\u7f13\u89e3\u75bc\u75db,\u540c\u65f6\u6291\u5236\u65b0\u9aa8\u5f62\u6210\u6765\u963b\u6b62\u9aa8\u7ed3\u6784\u8fdb\u4e00\u6b65\u635f\u4f24\u3002<\/p>\n\n\n\n
\u4f5c\u4e3a\u76ee\u524d\u5168\u7403\u9996\u4e2a\u4e14\u552f\u4e00\u5168\u4eba\u6e90IL-17A\u6291\u5236\u5242,\u591a\u9879\u4e34\u5e8a\u7814\u7a76\u8bc1\u5b9e\u4e86\u53ef\u5584\u633a\u00ae\u7684\u591a\u91cd\u83b7\u76ca:
\u00b7 \u5feb\u901f\u7f13\u89e3\u80cc\u75db\u3001\u6668\u50f5\u548c\u75b2\u4e4f\u75c7\u72b6\uff1aMEASURE 2\u7814\u7a76\u7ed3\u679c\u663e\u793a\uff0c\u60a3\u8005\u63a5\u53d7150mg\u53ef\u5584\u633a\u00ae\u6cbb\u75974\u5468\uff0c\u80cc\u75db\u8f83\u57fa\u7ebf\u6539\u558439%\uff08\u5b89\u6170\u5242\u7ec4\uff1a15%\uff09\uff0c\u6668\u50f5\u8f83\u57fa\u7ebf\u6539\u558434.4%\uff08\u5b89\u6170\u5242\u7ec4\uff1a14.8%\uff09\uff0c\u75b2\u52b3\u8f83\u57fa\u7ebf\u6539\u558428%\uff08\u5b89\u6170\u5242\u7ec4\uff1a8%\uff09\u3002
\u00b7 \u6291\u5236\u65b0\u9aa8\u5f62\u6210\uff0c\u963b\u6b62\u7ed3\u6784\u635f\u4f24\uff1a\u6301\u7eed\u63a5\u53d7\u53ef\u5584\u633a\u00ae\u6cbb\u7597\uff0c97%\u57fa\u7ebf\u65e0\u9aa8\u8d58\u60a3\u8005\u548c73%\u57fa\u7ebf\u6709\u9aa8\u8d58\u60a3\u80052\u5e74\u5185\u65e0\u65b0\u751f\u9aa8\u8d58\uff0c\u8fd180%\u60a3\u8005\u810a\u67f1\u635f\u4f24\u57284\u5e74\u5185\u672a\u51fa\u73b0\u6076\u5316\u3002
\u00b7 \u826f\u597d\u6574\u4f53\u5b89\u5168\u6027\u548c\u8010\u53d7\u6027\uff1aIL-17A\u5904\u4e8e\u6574\u4e2a\u708e\u75c7\u901a\u8def\u7684\u4e0b\u6e38\uff0c\u4e14\u5168\u4eba\u6e90\u5236\u5907\u5de5\u827a\u964d\u4f4e\u4e86\u4e0d\u826f\u53cd\u5e94\u98ce\u9669\u3002\u7814\u7a76\u663e\u793a\uff0c\u7ecf\u53ef\u5584\u633a\u00ae\u6cbb\u7597\u7684\u60a3\u8005\u5c1a\u65e0\u7ed3\u6838\u6613\u611f\u6027\u589e\u52a0\u7684\u62a5\u544a\uff0c\u4e14\u76ee\u524d\u5c1a\u672a\u89c1\u7ecf\u53ef\u5584\u633a\u00ae\u6cbb\u7597\u51fa\u73b0\u4e59\u809d\u518d\u6fc0\u6d3b\u7684\u76f8\u5173\u62a5\u9053\uff0c5\u5e74\u6297\u836f\u6297\u4f53\u53d1\u751f\u7387<1%\u3002<\/p>\n\n\n\n
\u4f5c\u4e3a\u53f8\u5e93\u5947\u5c24\u5355\u6297\u4e2d\u56fdIII\u671f\u4e34\u5e8a\u7814\u7a76\u8d1f\u8d23\u4eba,\u9ec4\u70fd\u6559\u6388\u4ecb\u7ecd:\u201c\u53f8\u5e93\u5947\u5c24\u5355\u6297\u7684\u51fa\u73b0\u65e0\u7591\u4e3a\u60a3\u8005\u63d0\u4f9b\u4e86\u4e00\u4e2a\u5168\u65b0\u7684\u6cbb\u7597\u9009\u62e9\u548c\u5e0c\u671b,\u4e5f\u8ba9\u6211\u4eec\u5bf9IL-17A\u8fd9\u4e00\u65b0\u9776\u70b9\u5728\u5f3a\u76f4\u6027\u810a\u67f1\u708e\u9886\u57df\u7684\u4e34\u5e8a\u8868\u73b0\u548c\u6f5c\u529b\u5145\u6ee1\u671f\u5f85\u3002\u5e0c\u671b\u770b\u5230\u66f4\u591a\u4e2d\u56fd\u60a3\u8005\u80fd\u83b7\u76ca\u4e8e\u65b0\u4e00\u4ee3\u7684\u521b\u65b0\u836f\u7269!\u201d<\/p>\n\n\n\n
\u76ee\u524d,\u53ef\u5584\u633a\u00ae\u5df2\u5728\u5305\u62ec\u6b27\u76df\u56fd\u5bb6\u548c\u7f8e\u56fd\u5728\u5185\u7684\u591a\u4e2a\u56fd\u5bb6\u548c\u5730\u533a\u4e0a\u5e02,\u6279\u51c6\u7528\u4e8e\u6cbb\u7597\u94f6\u5c51\u75c5\u3001\u94f6\u5c51\u75c5\u5173\u8282\u708e\u53ca\u5f3a\u76f4\u6027\u810a\u67f1\u708e,\u62e5\u67095\u5e74\u6301\u7eed\u6027\u7597\u6548\u548c\u5b89\u5168\u6027\u6570\u636e\u652f\u6301,\u60e0\u53ca\u5168\u7403\u8d85\u8fc730\u4e07\u60a3\u8005\u3002<\/p>\n\n\n\n
** \u6b32\u4e86\u89e3\u66f4\u591a\u6709\u5173\u53ef\u5584\u633a\u00ae(\u53f8\u5e93\u5947\u5c24\u5355\u6297)\u4ea7\u54c1\u4fe1\u606f\u53ca\u5b89\u5168\u6027\u6570\u636e,\u8bf7\u524d\u5f80\u8bfa\u534e\u4e2d\u56fd\u5b98\u7f51(www.novartis.com.cn)\u641c\u7d22\u201c\u53ef\u5584\u633a\u201d\u6216\u201c\u53f8\u5e93\u5947\u5c24\u5355\u6297\u201d\u83b7\u53d6\u5904\u65b9\u4fe1\u606f\u3002<\/p>\n\n\n\n
Disclaimer<\/p>\n\n\n\n
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as \u201cpotential,\u201d \u201ccan,\u201d \u201cwill,\u201d \u201cplan,\u201d \u201cmay,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201canticipate,\u201d \u201cseek,\u201d \u201clook forward,\u201d \u201cbelieve,\u201d \u201ccommitted,\u201d \u201cinvestigational,\u201d \u201cpipeline,\u201d \u201claunch,\u201d or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG\u2019s current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.<\/p>\n\n\n\n
\u5173\u4e8e\u8bfa\u534e<\/p>\n\n\n\n
\u8bfa\u534e\u6b63\u5728\u901a\u8fc7\u521b\u60f3\u533b\u836f\u672a\u6765\u4ee5\u6539\u5584\u4eba\u4eec\u751f\u6d3b\u8d28\u91cf\u3001\u5ef6\u957f\u4eba\u7c7b\u5bff\u547d\u3002\u4f5c\u4e3a\u5168\u7403\u77e5\u540d\u7684\u533b\u836f\u5065\u5eb7\u4f01\u4e1a,\u6211\u4eec\u8fd0\u7528\u521b\u65b0\u79d1\u5b66\u548c\u6570\u5b57\u5316\u6280\u672f,\u5728\u533b\u836f\u5065\u5eb7\u9700\u6c42\u589e\u957f\u7684\u9886\u57df\u521b\u9020\u53d8\u9769\u6027\u7684\u6cbb\u7597\u65b9\u6cd5\u3002\u5728\u63a2\u7d22\u65b0\u836f\u7269\u7684\u8fc7\u7a0b\u4e2d,\u6211\u4eec\u4e0d\u61c8\u521b\u65b0,\u5bf9\u7814\u53d1\u7684\u6295\u8d44\u4e00\u76f4\u5904\u4e8e\u884c\u4e1a\u5168\u7403\u5148\u5217\u3002\u5728\u5168\u7403,\u8d85\u8fc77.99\u4ebf\u60a3\u8005\u53d7\u76ca\u4e8e\u8bfa\u534e\u4ea7\u54c1,\u540c\u65f6,\u6211\u4eec\u6301\u7eed\u63a2\u7d22\u66f4\u591a\u521b\u65b0\u65b9\u5f0f\u4f7f\u6211\u4eec\u7684\u521b\u65b0\u7597\u6cd5\u9020\u798f\u66f4\u591a\u60a3\u8005\u3002\u8bfa\u534e\u5728\u5168\u7403\u62e5\u6709\u6765\u81ea\u8d85\u8fc7140\u4e2a\u56fd\u5bb6\u7684\u7ea610.9\u4e07\u540d\u5458\u5de5\u3002\u5982\u9700\u66f4\u591a\u4fe1\u606f,\u656c\u8bf7\u767b\u5f55\u516c\u53f8\u7f51\u7ad9:www.novartis.com \u3002<\/p>\n\n\n\n
\u5173\u4e8e\u8bfa\u534e\u4e2d\u56fd<\/p>\n\n\n\n
\u201c\u8bfa\u534e\u201d\u4e2d\u6587\u53d6\u610f\u201c\u627f\u8bfa\u4e2d\u534e\u201d,\u5373\u627f\u8bfa\u901a\u8fc7\u4e0d\u65ad\u521b\u65b0\u7684\u4ea7\u54c1\u548c\u670d\u52a1,\u81f4\u529b\u4e8e\u63d0\u9ad8\u4e2d\u56fd\u4eba\u6c11\u7684\u5065\u5eb7\u6c34\u5e73\u548c\u751f\u6d3b\u8d28\u91cf\u3002\u8bfa\u534e\u5728\u4e2d\u56fd\u7684\u4e1a\u52a1\u5305\u62ec\u8bfa\u534e\u80bf\u7624\u3001\u8bfa\u534e\u5236\u836f\u548c\u5c71\u5fb7\u58eb,\u5168\u56fd\u5efa\u6709\u4e24\u5927\u751f\u4ea7\u57fa\u5730,\u5e76\u5728\u5317\u4eac\u3001\u4e0a\u6d77\u548c\u6c5f\u82cf\u8bbe\u7acb\u4e86\u7814\u53d1\u673a\u6784\u3002\u4ece\u7814\u53d1\u5230\u751f\u4ea7\u9500\u552e,\u8bfa\u534e\u4ee5\u591a\u5143\u5316\u7684\u4e1a\u52a1\u7ec4\u5408,\u5168\u9762\u670d\u52a1\u4e2d\u56fd\u8001\u767e\u59d3\u7684\u5065\u5eb7\u3002\u76ee\u524d,\u8bfa\u534e\u5728\u4e2d\u56fd\u62e5\u67098000\u591a\u540d\u5458\u5de5\u3002\u5982\u9700\u66f4\u591a\u4fe1\u606f,\u656c\u8bf7\u767b\u5f55\u516c\u53f8\u4e2d\u6587\u7f51\u7ad9http:\/\/www.novartis.com.cn\u3002<\/p>\n\n\n\n
1.\u4e2d\u534e\u533b\u5b66\u4f1a\u98ce\u6e7f\u75c5\u5b66\u5206\u4f1a. \u5f3a\u76f4\u6027\u810a\u67f1\u708e\u8bca\u65ad\u53ca\u6cbb\u7597\u6307\u5357. \u4e2d\u56fd\u98ce\u6e7f\u75c5\u5b66\u6742\u5fd7,2010,14(8):557-560.<\/p>\n\n\n\n
2.\u6839\u636e\u56fd\u5bb6\u7edf\u8ba1\u5c40\u5b98\u7f51\u516c\u5e03\u76842010\u5e74\u7b2c\u516d\u6b21\u4eba\u53e3\u666e\u67e5\u6570\u636e,\u6211\u56fd\u6210\u5e74\u4eba\u53e3\u6570\u7ea610.5\u4ebf\u3002\u4ee5\u6b64\u6570\u636e\u4e3a\u57fa\u7840\u8fdb\u884c\u5321\u7b97\u3002<\/p>\n\n\n\n
3.Ward MM. Arthritis Care Res. 1999:12(4):247-255.<\/p>\n\n\n\n
4.Druce KL et al. Arthritis Res Ther. 2018;20(l):96.<\/p>\n\n\n\n
5.\u6d82\u67f3\u4e39 \u7b49,\u300a\u4e2d\u5c71\u5927\u5b66\u5b66\u62a5:\u533b\u5b66\u79d1\u5b66\u7248\u300b2015\u5e74 \u7b2c1\u671f<\/p>\n\n\n\n
6.Lories R, Melones 1B. Nature Medicine 2012-18:1018-19<\/p>\n\n\n\n
7.Patel DD, et al. Ann Rheum Dis. 2013;72 (Suppl 2), ii116-23.<\/p>\n\n\n\n
8.Moynes DM et al. Brain Behav Immun. 2014 Oct;41:1-9.<\/p>\n\n\n\n
9.Bidad K et al. Nat Rev Rheumatol. 2017 Jul;13(7):410-420.<\/p>\n\n\n\n
10.Sun C et al. Mol Med Rep. 2017 Jan;15(1):89-96.<\/p>\n\n\n\n
11.Koenders MI, et al. Drug Des Devel Ther. 2016 Jun 24;102069-80.<\/p>\n\n\n\n
12.Deodhar A,et al. Clin Exp Rheumatol. 2019 Mar-Apr;37(2):260-269.<\/p>\n\n\n\n
13.Marzo-Ortega et al. 2019 ACR Annual Meeting. Poster 1504<\/p>\n\n\n\n
14.Braun J et al. Ann Rheum Dis. 2017;76(6):1070-1077 and Supplementary Tables<\/p>\n\n\n\n
15.Braun J et al. Rheumatology (Oxford). 2019;58(5):859-868.<\/p>\n\n\n\n
16.Hannah A. Blair. Drugs (2019) 79:433\u2013443<\/p>\n\n\n\n
17.PubMed\u68c0\u7d22(201501-202002)\u7ed3\u679c\u622a\u56fe<\/p>\n\n\n\n
18.Reich K et al. J Eur Acad Dermatol Venereol. 2019;33(9):1733-1741.<\/p>\n\n\n\n
19.Novartis Europharm Limited. Cosentyx (secukinumab): Summary of Product Characteristics. Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/medicines\/human\/medicines\/003729\/human_med_001832.jsp&mid=WC0b01ac058001d124 [Last accessed: January 2020].<\/p>\n\n\n\n
20.Girolomoni G, et al. Psoriasis: Rationale for targeting interleukin-17. Br J Dermatol 2012;167:717\u2013724.<\/p>\n\n\n\n
21.Sieper J, et al. The IL-23\u2013IL-17 pathway as a therapeutic target in axial spondyloarthritis. Nat Rev Rheumatol 2019; 15:747\u2013757.<\/p>\n\n\n\n
22.Brembilla NC, Senra L, Boehncke W-H. The IL-17 Family of Cytokines in Psoriasis: IL-17A and Beyond. Front. Immunol. 9:1682. doi: 10.3389\/fimmu.2018.01682.<\/p>\n\n\n\n
23.Baraliakos X, et al. Long-term evaluation of secukinumab in ankylosing spondylitis: 5-year efficacy and safety results from a Phase 3 trial. Presented as a late-breaking abstract at the American College of Rheumatology Annual Meeting; October 19\u201324, 2018; Chicago, IL.<\/p>\n\n\n\n
24.Bissonnette R, et al. Secukinumab demonstrates high sustained efficacy and a favorable safety profile through 5 years of treatment in moderate to severe psoriasis. J Eur Acad Dermatol Venereol 2018;32:1507\u20131514.<\/p>\n\n\n\n
25.Mease PJ, et al. Secukinumab provides sustained improvements in the signs and symptoms of psoriatic arthritis: Final 5-year results from the Phase 3 FUTURE 1 study. ACR Open Rheumatol 2019. doi: 10.1002\/acr2.11097 [Epub ahead of print].<\/p>\n\n\n\n
26.Novartis data on file.<\/p>\n","protected":false},"excerpt":{"rendered":"
\u8bfa\u534e\u53ef\u5584\u633a\uff08\u53f8\u5e93\u5947\u5c24\u5355\u6297\uff09\u5f3a\u76f4\u6027\u810a\u67f1\u708e\u9002\u5e94\u75c7\u83b7\u6279\u65f6\u95f4\uff1a202…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-5736","post","type-post","status-publish","format-standard","hentry","category-itzixun"],"_links":{"self":[{"href":"http:\/\/www.speakingsh.com\/index.php?rest_route=\/wp\/v2\/posts\/5736","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/www.speakingsh.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"http:\/\/www.speakingsh.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"http:\/\/www.speakingsh.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.speakingsh.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=5736"}],"version-history":[{"count":1,"href":"http:\/\/www.speakingsh.com\/index.php?rest_route=\/wp\/v2\/posts\/5736\/revisions"}],"predecessor-version":[{"id":5738,"href":"http:\/\/www.speakingsh.com\/index.php?rest_route=\/wp\/v2\/posts\/5736\/revisions\/5738"}],"wp:attachment":[{"href":"http:\/\/www.speakingsh.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=5736"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"http:\/\/www.speakingsh.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=5736"},{"taxonomy":"post_tag","embeddable":true,"href":"http:\/\/www.speakingsh.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=5736"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}